• Tevogen entered a signed, non-exclusive, non-binding letter of intent to evaluate a potential acquisition of HRK Healthcare.
• The deal could expand healthcare infrastructure capabilities, adding to a planned services arm alongside Tevogen Bio and Tevogen.AI.
• The transaction remains subject to due diligence, definitive agreements, required approvals, and customary closing conditions.
• Management cited a potential path to about $100 million in combined annual revenue if completed with other acquisition initiatives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610081410PRIMZONEFULLFEED9842419) on October 08, 2026, and is solely responsible for the information contained therein.